RetinAI is a technology company that specializes in creating a data management platform integrated with AI modules, designed to improve understanding of patients' diseases and outcomes through enhanced insights and knowledge.

RetinAI

RetinAI is a Swiss & US-based software company improving and supporting R&D of first-in-human drug candidates, supercharging management and oversight of clinical trials and enabling the research needed to elevate the quality of care on patients with eye diseases. 

We achieve this goal by building tools to collect, analyze and to organize health data. Our fundamental belief is that in the future every patient will use drugs alongside a digital application that will enable them and their physicians to better assess the right drug, in the right amount and the right frequency for patients.



Eurostars

Venture Kick

Matterwave Ventures

btov Partners

Verve Ventures

Retinai

BSI has certified our platform RetinAI Discovery and 3 of our #AI models under the Medical Devices Regulation EU 2017/745! This certification underscores our commitment to excellence and compliance with the highest industry standards.

What this means: 
👉 Our quality management system met the rigorous requirements of the EU Medical Device Regulation (EU) 2017/745, ensuring top-tier safety and effectiveness.
👉 Our advanced ophthalmology assessment and diagnostic support technologies, including RetinAI's AI models for Macula Biomarkers, Layer Segmentation and Fluid Segmentation models, have been validated and recognized to meet a healthcare need.
👉 With this certification, we strengthen our position as a trusted pioneer in the AI healthcare technology space.

This milestone is a testament to our team's dedication and the robust quality systems we have in place. Thank you to our team, partners, and clients for their unwavering support.

Together, we are shaping the future of eye care!

For more information, read the press release 👉 https://lnkd.in/ecsjmHQW 

#MDRCertification #AIinHealthcare #Innovation #QualityAssurance #HealthcareTech Ikerian

On Monday, some of our Retinauts gathered for a fantastic barbecue party under the sunny skies of Switzerland's beautiful capital 😎

From exciting games to the Rodelbahn ride, the day was filled with fun and laughter. Our team showed that work and play can blend perfectly!

A big shoutout to our Swiss-based team for organizing such a memorable event. We can't wait for the next adventure!

#TeamBuilding #Retinauts #SwissAdventures #WorkHardPlayHard #CompanyCulture #BernFun

Only 1 week left! Meet Aunia Grogan, our VP Business Development at the 2nd Annual Retinal Imaging Biomarkers & Endpoints Summit in Boston from June 25 to 27.

Aunia looks forward to joining this exciting forum and connecting with leading retinal experts like you!

Schedule your meeting with Aunia to get an overview of our solutions 👉 https://lnkd.in/e5U7kk2Y

See you in Boston!

We're excited to announce that Carlos Ciller, our co-founder and CEO will be a panelist today at the Swiss Medtech Day!

Join the session "The Promise of AI and Large Language Models (LLM) to Transform Healthcare" at 11:30 AM and 2:00 PM.

In this session, we'll explore how AI and LLM are revolutionizing medical device design and the broader healthcare industry. 

Discover the potential and challenges of integrating AI into medical products, from improved diagnostic and predictive analytics to the complexities of regulatory compliance and data privacy.

We look forward to engaging in meaningful discussions about the future of AI in healthcare. If you're attending the event, don't miss this insightful session!

Learn more about the event: https://lnkd.in/e2iscuDb

#SwissMedtechDay #AIinHealthcare #MedicalInnovation #HealthcareTechnology #AIandLLM #RetinAI

We recently sponsored a CPD-registered seminar led by the renowned Prof. Paulo Eduardo Stanga at The Retina Clinic London. This event focused on the state-of-the-art Diagnostic Technologies and Techniques in Retina, and on how AI is transforming clinical workflows in Ophthalmology!

Key highlights of the event:

✅ AI can reshape clinical practice and support diagnostics
✅ AI is integral to streamlining workflows and saving time
✅ Case studies highlighted the potential of AI to revolutionize treatment and patient care

We believe in innovation and are dedicated to supporting those who strive to make a difference.

AI is a powerful tool for healthcare professionals, enabling them to tackle challenging cases more effectively.

If you want to have a demo or get to know our solutions better, visit our website 👉 https://www.retinai.com/

#AIinHealthcare #Ophthalmology #Innovation #ClinicalWorkflows #HealthcareRevolution #FutureOfDiagnostics #MedicalInnovation #AI #HealthcareProfessionals #Eyecare


In a few weeks, we will be participating in the Retinal Imaging Biomarkers & Endpoints Summit in Boston!

From June 25 to 27, you can meet Aunia Grogan at the Hilton Boston Back Bay who will walk you through our data and AI solutions, showing you how RetinAI Discovery can enhance and accelerate imaging analysis for biomarkers, and optimize clinical trial workflows.

If you are attending the Summit, schedule a meeting with Aunia in advance 👉 https://lnkd.in/eF7CXeB3

#ophthalmology #eyecare #research #clinicalresearch #healthcare #digitalhealthcare #artificialintelligence #machinelearning

msh id	COM:RETINAI
symbol	-
name	RetinAI
homepage url	https://retinai.com
country	CH
sector	Healthcare & Health Services
industry	Healthcare Technology
market	PRIVATE
employee count	38
crunchbase url	https://www.crunchbase.com/organization/retinai-medical
linkedin url	https://www.linkedin.com/company/retinai
founders	-

market cap	-
enterprise value	-
stage	Series B
raised capital	7.8M
valuation	-

monthly webtraffic	9.75K
monthly webtraffic growth	0.67
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-
growth cost of revenue	-
growth depreciation and amortization	-
growth ebitda	-
growth ebitda ratio	-
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	-
growth gross profit ratio	-

COM:RETINAI

RetinAI

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	-
cost of revenue	-
depreciation and amortization	-
ebitda	-
ebitda ratio	-
eps	-
eps diluted	-
operating expenses	-
operating income	-
operating income ratio	-

accounts receivables	-
capital expenditure	-
cash at beginning of period	-
cash at end of period	-
inventory	-
working capital ttm	-

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-